Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 13/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | GAK | O14976 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3751674 | 0.92 | HSD17B10 (0.43) | PRKDCHSD17B10ARPIK3CDPIK3CA | |
| SCHEMBL3758948 | 0.82 | PIK3CD (0.42) | PRKDCHSD17B10ARPIK3CDPIK3CA | |
| SCHEMBL4569738 | 0.81 | PIK3CA (0.44) | PRKDCARPIK3CDPIK3CAPIK3CB | |
| SCHEMBL3754789 | 0.76 | LRRK2 (0.42) | PRKDCHSD17B10PIK3CA | |
| SCHEMBL3765770 | 0.76 | AOC3 (0.37) | PIK3CDPIK3CA | |
| SCHEMBL3757639 | 0.75 | PIK3CD (0.41) | PRKDCHSD17B10PIK3CDPIK3CAPIK3CB | |
| SCHEMBL3759120 | 0.74 | PARP1 (0.39) | PIK3CA | |
| SCHEMBL16161774 | 0.74 | GRM5 (0.46) | PRKDCHSD17B10PIK3CDPIK3CAPIK3CB | |
| SCHEMBL3764951 | 0.74 | PIK3CD (0.40) | PRKDCHSD17B10PIK3CDPIK3CAPIK3CB | |
| SCHEMBL3754629 | 0.72 | BMPR1B (0.37) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | PRKDC 112/4885HSD17B10 2922/4885AR 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.